The UK and US have reached a major trade agreement that will keep no import taxes on UK medicine products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on medicines through the National Health Service (NHS). This move guarantees that import taxes on these key exports will remain at nothing for a period of three years.
This agreement is in response to previous statements to dramatically increase tariffs on patented drug imports, with figures discussed reaching one hundred percent.
"This agreement with the Britain strengthens the global environment for cutting-edge drugs and brings much-needed fairness to U.S.–U.K. medicine commerce," a release noted.
Commercial Significance
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the United States, which is by far the primary market for major British pharmaceutical firms.
Statistics indicate that in the year prior to last September, the UK shipped medicines totaling over eleven billion pounds to the US. This value accounted for nearly one-fifth of British export trade in that period.
"This agreement safeguards employment, increases capital expenditure and paves the way for the UK to become a worldwide center for life sciences," a government official commented.
Detailed NHS Changes
The pact entails several notable commitments from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded twenty percent.
Recent Tensions
The deal comes amid a ongoing row between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
These tensions were intensified by claims that US consumers were charged several times more for the equivalent treatments than patients in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been paused or cancelled, while substantial investments have been pledged toward American operations.
A senior figure acknowledged that the NHS had to increase expenditure on drugs, noting that its spending on drugs had decreased as a percentage of its overall budget over the past decade.
